{"id":"NCT01275196","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients","officialTitle":"ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2011-01-12","resultsPosted":"2015-12-09","lastUpdate":"2016-04-08"},"enrollment":267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"Nilotinib","otherNames":[]},{"type":"DRUG","name":"Imatinib","otherNames":[]}],"arms":[{"label":"Nilotinib","type":"EXPERIMENTAL"},{"label":"Imatinib","type":"ACTIVE_COMPARATOR"}],"summary":"The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.","primaryOutcome":{"measure":"Major Molecular Response (MMR) at 12 Months - With Imputation.","timeFrame":"12 months","effectByArm":[{"arm":"Imatinib","deltaMin":27.8,"sd":null},{"arm":"Nilotinib","deltaMin":52.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":26},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":["25766724"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":132},"commonTop":["Thrombocytopenia","Lipase increased","Rash","Leukopenia","Platelet count decreased"]}}